Literature DB >> 17712819

Human cannabinoid pharmacokinetics.

Marilyn A Huestis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17712819      PMCID： PMC2689518          DOI： 10.1002/cbdv.200790152

Source DB:  PubMed          Journal:  Chem Biodivers        ISSN： 1612-1872            Impact factor:   2.408


× No keyword cloud information.
  159 in total

1.  On-site testing of saliva and sweat with Drugwipe and determination of concentrations of drugs of abuse in saliva, plasma and urine of suspected users.

Authors:  N Samyn; C van Haeren
Journal:  Int J Legal Med       Date:  2000       Impact factor: 2.686

2.  The determination of 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) in hair using negative ion gas chromatography-mass spectrometry and high-volume injection.

Authors:  C Moore; F Guzaldo; T Donahue
Journal:  J Anal Toxicol       Date:  2001-10       Impact factor: 3.367

Review 3.  Pharmacokinetics of THC in brain and testis, male gametotoxicity and premature apoptosis of spermatozoa.

Authors:  Gabriel G Nahas; Henry Clay Frick; John K Lattimer; Colette Latour; David Harvey
Journal:  Hum Psychopharmacol       Date:  2002-03       Impact factor: 1.672

4.  Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997.

Authors:  M A ElSohly; S A Ross; Z Mehmedic; R Arafat; B Yi; B F Banahan
Journal:  J Forensic Sci       Date:  2000-01       Impact factor: 1.832

5.  Temporal indication of marijuana use can be estimated from plasma and urine concentrations of delta9-tetrahydrocannabinol, 11-hydroxy-delta9-tetrahydrocannabinol, and 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid.

Authors:  J E Manno; B R Manno; P M Kemp; D D Alford; I K Abukhalaf; M E McWilliams; F N Hagaman; M J Fitzgerald
Journal:  J Anal Toxicol       Date:  2001-10       Impact factor: 3.367

6.  The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis.

Authors:  A M Malfait; R Gallily; P F Sumariwalla; A S Malik; E Andreakos; R Mechoulam; M Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

7.  Monitoring urinary excretion of cannabinoids by fluorescence-polarization immunoassay: a cannabinoid-to-creatinine ratio study.

Authors:  Albert D Fraser; David Worth
Journal:  Ther Drug Monit       Date:  2002-12       Impact factor: 3.681

8.  Partition coefficient, blood to plasma ratio, protein binding and short-term stability of 11-nor-Delta(9)-carboxy tetrahydrocannabinol glucuronide.

Authors:  Gisela Skopp; Lucia Pötsch; Martin Mauden; Barbara Richter
Journal:  Forensic Sci Int       Date:  2002-03-28       Impact factor: 2.395

9.  In vitro experiment optimization for measuring tetrahydrocannabinol skin permeation.

Authors:  Prasad V N Challapalli; Audra L Stinchcomb
Journal:  Int J Pharm       Date:  2002-07-25       Impact factor: 5.875

10.  Cannabinoids control spasticity and tremor in a multiple sclerosis model.

Authors:  D Baker; G Pryce; J L Croxford; P Brown; R G Pertwee; J W Huffman; L Layward
Journal:  Nature       Date:  2000-03-02       Impact factor: 49.962
View more
  238 in total

1.  THC and CBD blood and brain concentrations following daily administration to adolescent primates.

Authors:  S L Withey; J Bergman; M A Huestis; S R George; B K Madras
Journal:  Drug Alcohol Depend       Date:  2020-06-18       Impact factor: 4.492

2.  Pharmacokinetics of Cannabis Brownies: A Controlled Examination of Δ9-Tetrahydrocannabinol and Metabolites in Blood and Oral Fluid of Healthy Adult Males and Females.

Authors:  Tory R Spindle; Edward J Cone; Evan S Herrmann; John M Mitchell; Ronald Flegel; Charles LoDico; George E Bigelow; Ryan Vandrey
Journal:  J Anal Toxicol       Date:  2020-10-12       Impact factor: 3.367

3.  Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.

Authors:  Lisa K Brents; Anna Gallus-Zawada; Anna Radominska-Pandya; Tamara Vasiljevik; Thomas E Prisinzano; William E Fantegrossi; Jeffery H Moran; Paul L Prather
Journal:  Biochem Pharmacol       Date:  2012-01-18       Impact factor: 5.858

4.  The pharmacokinetic disposition of delta-9-tetrahydrocannabinol and its metabolite in elderly patients with dementia--role of differential presystemic conversion?

Authors:  Nuggehally R Srinivas
Journal:  Psychopharmacology (Berl)       Date:  2015-11-05       Impact factor: 4.530

5.  Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD).

Authors:  Matthew W Elmes; Martin Kaczocha; William T Berger; KwanNok Leung; Brian P Ralph; Liqun Wang; Joseph M Sweeney; Jeremy T Miyauchi; Stella E Tsirka; Iwao Ojima; Dale G Deutsch
Journal:  J Biol Chem       Date:  2015-02-09       Impact factor: 5.157

6.  Cannabis and Pediatric Inflammatory Bowel Disease: Change Blossoms a Mile High.

Authors:  Edward J Hoffenberg; Heike Newman; Colm Collins; Sally Tarbell; Kristina Leinwand
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-02       Impact factor: 2.839

7.  Evaluation of reinforcing and aversive effects of voluntary Δ9-tetrahydrocannabinol ingestion in rats.

Authors:  Daniel G Barrus; Timothy W Lefever; Jenny L Wiley
Journal:  Neuropharmacology       Date:  2018-05-03       Impact factor: 5.250

8.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

Review 9.  A Comprehensive Review of Cannabis in Patients with Cancer: Availability in the USA, General Efficacy, and Safety.

Authors:  Grant Steele; Tom Arneson; Dylan Zylla
Journal:  Curr Oncol Rep       Date:  2019-02-01       Impact factor: 5.075

Review 10.  Cannabinoid signalling and effects of cannabis on the male reproductive system.

Authors:  Mauro Maccarrone; Cinzia Rapino; Felice Francavilla; Arcangelo Barbonetti
Journal:  Nat Rev Urol       Date:  2020-11-19       Impact factor: 14.432
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.